CoChat

MET amplification in metastatic colorectal cancer: an acquired response to EGFR inhibition, not a de novo phenomenon

Open access
Raghav, Kanwal, Morris, Van, Tang, Chad, Morelli, Pia, Amin, Hesham M., Chen, Ken, Manyam, Ganiraju C., Broom, Bradley, Overman, Michael J., Shaw, Kenna, Meric-Bernstam, Funda, Maru, Dipen, Menter, David, Ellis, Lee M., Eng, Cathy, Hong, David, Kopetz, Scott · 2016 · Oncotarget
Cited by 77

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

// Kanwal Raghav 1 , Van Morris 1 , Chad Tang 2 , Pia Morelli 1 , Hesham M. Amin 3 , Ken Chen 4 , Ganiraju C. Manyam 4 , Bradley Broom 4 , Michael J. Overman 1 , Kenna Shaw 5 , Funda Meric-Bernstam 6 , Dipen Maru 3 , David Menter 1 , Lee M. Ellis 7 , Cathy Eng 1 , David Hong 6 , Scott Kopetz 1 1 Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA 2 Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA 3 Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA 4 Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA 5 Sheikh Khalifa Bin Zayed Al Nahyan Institute of Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA 6 Department of Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA 7 Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA Correspondence to: Scott Kopetz, email: skopetz@mdanderson.org Keywords: amplification, MET, circulating-free DNA, fluorescence in situ hybridization, colorectal cancer Received: March 14, 2016 Accepted: May 05, 2016 Published: July 13, 2016 ABSTRACT Background: MET amplification appears to be a predictive biomarker for MET inhibition. Prior studies reported a MET amplification rate of 9–18% in metastatic colorectal cancer (mCRC) but do not differentiate increased gene copy numbers due to chromosomal level aberrations from focal gene amplifications. Validation of MET amplification rate in mCRC is critical to this field. Results: In tumor tissue-based analyses, overall MET amplification rate was 1.7% (10/590). MET amplification was seen in 0/103 (0%), 4/208 (1.9%) and 6/279 (2.2%) cases, in cohorts 1, 2 and 3, respectively. Rate of MET amplification in cfDNA of cohort 4 patients refractory to anti-EGFR therapy ( n = 53) was 22.6% (12/53) and was significantly higher compared to patients not exposed to anti-EGFR therapy ( p < 0.001). Materials and Methods: We analyzed MET amplification in mCRC ( n = 795) using different methods across multiple cohorts. Cohort 1 ( n = 103) and 2 ( n = 208) included resected liver metastases and tumor biopsies, respectively, tested for MET amplification using fluorescence in-situ hybridization [amplification: MET/CEP7 ratio ≥ 2.0]. Using another tissue-based approach, cohort 3 ( n = 279) included tumor biopsies sequenced with HiSeq (Illumina) with full exome coverage for MET [amplification: ≥ 4 copies identified by an in-house algorithm]. Using a blood-based approach by contrast, cohort 4 ( n = 205) included patients in whom the full exome of MET in circulating-free DNA (cfDNA) was sequenced with HiSeq. Conclusions: Contrary to prior reports, in this large cohort, MET amplification was a rare event in mCRC tissues. In plasma by stark contrast, MET amplification identified by cfDNA occurred in a sizable subset of patients that are refractory to anti-EGFR therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.10559

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 77

Metadata

Authors
Raghav, K., Morris, V., Tang, C., Morelli, P., Amin, H. M., Chen, K., Manyam, G. C., Broom, B., Overman, M. J., Shaw, K., Meric-Bernstam, F., Maru, D., Menter, D., Ellis, L. M., Eng, C., Hong, D., & Kopetz, S.
Venue
Oncotarget
Published
2016-07-13
Volume
7
Issue
34
Pages
54627-54631
ISSN
1949-2553 (ISSN-L)
OpenAlex
W2461784407
Cited by
77
References
2
FWCI
4.17
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: MET amplification in metastatic colorectal cancer: an acquired response to EGFR inhibition, not a de novo phenomenon. https://app.cochat.ai/papers/10.18632/oncotarget.10559
The paper
Raghav, K., Morris, V., Tang, C., Morelli, P., Amin, H. M., Chen, K., Manyam, G. C., Broom, B., Overman, M. J., Shaw, K., Meric-Bernstam, F., Maru, D., Menter, D., Ellis, L. M., Eng, C., Hong, D., & Kopetz, S. (2016). MET amplification in metastatic colorectal cancer: an acquired response to EGFR inhibition, not a de novo phenomenon. Oncotarget. https://doi.org/10.18632/oncotarget.10559

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.